Source link : https://www.newshealth.biz/health-news/nivolumab-regimen-achieves-durable-pfs-in-advanced-hodgkins-lymphoma/
Adding nivolumab (Opdivo) instead of brentuximab vedotin (Adcetris) to the standard chemotherapy backbone of doxorubicin (Adriamycin), vinblastine, and dacarbazine (AVD) resulted in longer progression-free survival (PFS) in adolescents and adults with advanced-stage classic Hodgkin’s lymphoma, longer follow-up of the SWOG S1826 trial showed. Among 970 patients in the intention-to-treat population, the 2-year PFS rates were […]
Author : News Health
Publish date : 2024-10-16 21:00:00
Copyright for syndicated content belongs to the linked Source.